Cited by 54Schizophrenia research and treatmentElectroconvulsive Therapy StudiesNeurotransmitter Receptor Influence on Behavior

Neuroleptic discontinuation syndromes

Tranter, Richard, Healy, David·1998·Journal of Psychopharmacology

Abstract

The existence of discontinuation syndromes following treatment with neuroleptic (antipsychotic) drugs was first outlined in the mid-1960s but the effects of such syndromes have been neglected since then. We have pursued evidence for the existence and nature of discontinuation syndromes following neuroleptics through reports of difficulties following the use of dopamine blocking anti-emetics, the use of chlorpromazine to treat tuberculosis, the use of antidepressant-neuroleptic combinations in affective disorders, the occurrence of tardive syndromes and studies designed to establish the existence of discontinuation syndromes in schizophrenia. Combined these bodies of data point strongly to the existence of discontinuation syndromes after cessation of treatment with neuroleptics which may involve features other than motor dyskinesias. There is at present little evidence on the relative frequency of such syndromes or predisposing factors. The area needs research input to establish the nature of the syndromes that may result, their frequency, predisposing factors and best methods of treatment.

Integrity signals

Registry

Crossref · 10.1177/026988119801200412

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Tranter, R., & Healy, D.
Affiliations
North Wales Department of Psychological Medicine, Hergest Unit, Bangor LL57 2PW, UK
Venue
Journal of Psychopharmacology
Published
1998-07
Volume
12
Issue
4
Pages
401-406
ISSN
  • 0269-8811 (ISSN-L)
  • 1461-7285
OpenAlex
W2069460670
Cited by
54
References
34
Citations by year
2025: 1 · 2023: 1 · 2021: 3 · 2020: 2 · 2019: 4 · 2018: 1 · 2017: 1 · 2016: 1 · 2014: 3 · 2013: 2 · 2012: 1
FWCI
0.65
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Psychopharmacology (publishedVersion)
  • PubMed (publishedVersion)
  • ORCA Online Research @Cardiff (Cardiff University) (submittedVersion)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Keywords
antipsychotic drugs, chlorpromazine, tardive dyskinesia, tuberculosis treatment, mood disorders, schizophrenia, treatment withdrawal
MeSH terms
Antiemetics, Chlorpromazine, Dyskinesia, Drug-Induced, Humans, Psychotic Disorders, Substance Withdrawal Syndrome, Antipsychotic Agents, Mood Disorders, Substance-Related Disorders

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review